Atlantic Trust Group LLC lowered its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 12.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,676 shares of the pharmaceutical company’s stock after selling 4,796 shares during the quarter. Atlantic Trust Group LLC’s holdings in GlaxoSmithKline were worth $1,277,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in GSK. We Are One Seven LLC increased its position in shares of GlaxoSmithKline by 185.1% during the 1st quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 1,738 shares in the last quarter. Adviser Investments LLC acquired a new stake in shares of GlaxoSmithKline during the 1st quarter worth about $117,000. Toronto Dominion Bank increased its position in shares of GlaxoSmithKline by 133.3% during the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,800 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of GlaxoSmithKline during the 1st quarter worth about $135,000. Finally, Wealthcare Advisory Partners LLC increased its position in shares of GlaxoSmithKline by 80.8% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,570 shares of the pharmaceutical company’s stock worth $139,000 after purchasing an additional 1,595 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.
A number of brokerages have commented on GSK. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Thursday, March 22nd. BNP Paribas raised shares of GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Morgan Stanley raised shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a report on Thursday, March 22nd. Finally, Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, April 9th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $40.21.
GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.02). The business had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. analysts expect that GlaxoSmithKline plc will post 2.79 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 12th. Stockholders of record on Friday, May 11th will be paid a $0.5298 dividend. This represents a $2.12 annualized dividend and a dividend yield of 5.26%. The ex-dividend date of this dividend is Thursday, May 10th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 72.92%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.